Entera Bio Ltd. (ENTX) - 10-Q Summary for Period Ended June 30, 2026
Business Context and Reporting Period
Entera Bio Ltd. is a clinical-stage biopharmaceutical company developing first-in-class oral peptides for chronic conditions, primarily utilizing its proprietary N-Tab® platform. The company focuses on osteoporosis (EB613), hypoparathyroidism (EB612), and obesity/metabolic disorders (EB618). This report covers the quarterly period ended June 30, 2026. The company is incorporated in Israel and listed on the Nasdaq Capital Market.
Key Financial Metrics
| Metric (in thousands, except per share) | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Revenues | $0 | $42 |
| Operating Expenses | $8,102 | $5,231 |
| Operating Loss | $(8,102) | $(5,231) |
| Net Loss | $(10,817) | $(5,223) |
| Loss Per Share (Basic & Diluted) | $(0.22) | $(0.12) |
| Cash and Cash Equivalents (End of Period) | $11,309 | $10,858 |
| Total Cash, Cash Equivalents, and Restricted Cash | $18,526 | $18,954 |
| Accumulated Deficit | $(136,183) | $(119,150) |
| Net Cash Used in Operating Activities | $(6,554) | $(3,035) |
| Net Cash Provided by Financing Activities | $10,089 | $13,286 |
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss for the six months ended June 30, 2026, increased by 107% to $10.8 million compared to $5.2 million in the prior year period. This was driven by a 106% increase in Research and Development (R&D) expenses to $5.5 million and a significant increase in financial expenses.
- R&D Expense Growth: R&D expenses rose primarily due to preparation for the EB613 Phase 3 program ($1.1 million increase), expanded collaboration activities with OPKO for EB612 and EB618 ($1.1 million increase), and a Phase 1 bridging study for EB613 ($0.3 million increase).
- Financial Expenses: Financial expenses increased from a net income of $8,000 in 2025 to an expense of $2.7 million in 2026. This was primarily due to the fair value remeasurement of pre-funded warrants issued in April 2026, which were classified as a liability.
- Revenue: The company reported no revenue for the six months ended June 30, 2026, compared to $42,000 in the prior year period derived from a completed research services agreement.
Guidance, Outlook, and Risks
- EB613 Phase 3: The FDA accepted the company's plan for a Phase 3 registrational trial for EB613 (oral PTH for osteoporosis) in approximately 750 postmenopausal women. The primary endpoint is total hip BMD at Month 12. The company plans to initiate this study in late 2026.
- EB612 and EB618: Collaboration with OPKO was expanded to include the development of EB612 (oral PTH for hypoparathyroidism) and EB618 (oral GLP-1/Glucagon for obesity). Preclinical data for both programs were presented at ENDO 2026, supporting continued development.
- Liquidity and Capital Resources: As of June 30, 2026, the company held $18.5 million in total cash. However, a significant subsequent event occurred on July 28, 2026, when the company completed a private placement raising approximately $275.0 million in gross proceeds. Management believes these funds will support operations into 2030.
- Going Concern: Following the July 2026 financing, management concluded that substantial doubt regarding the company's ability to continue as a going concern no longer exists.
- Risks: Key risks include the uncertainty of clinical trial outcomes, regulatory approval processes, and the ongoing geopolitical conflict in the Middle East (Israel-Hamas-Iran). While operations were largely unaffected as of June 30, 2026, the company notes the potential for escalation to impact its workforce and supply chain.
Investor Verification Checklist
- Subsequent Financing: Verify the final net proceeds and terms of the July 2026 private placement ($275M gross) and its impact on share count and dilution.
- EB613 Phase 3 Timeline: Confirm the actual initiation date of the Phase 3 trial planned for late 2026 and patient enrollment progress.
- Pre-Funded Warrants Liability: Monitor the fair value adjustments of the April 2026 pre-funded warrants, which caused a $2.7M non-cash expense in Q2 and may continue to impact net loss.
- OPKO Collaboration Terms: Review the specific cost-sharing and milestone obligations under the amended collaboration agreement for EB612 and EB618.
- Geopolitical Impact: Assess any emerging disruptions to the company's Israeli-based research personnel or supply chain due to the ongoing regional conflict.